Feminizing Treatment in Transgender Women and Non-binary Persons

Feminizing Treatment in Transgender Women and Non-binary Persons BODY IDENTITY CLINIC - ESTROGEN

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05169762

Acronym

BIC-Estrogen

Enrollment

100

Registered

2021-12-27

Start date

2022-02-01

Completion date

2035-09-01

Last updated

2025-03-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transgenderism

Keywords

gender affirming hormone treatment, estrogen, cardiovascular risk

Brief summary

Cohort study in 100 transgender women treated with gender affirming hormone treatment. Follow up affter 1year, 3 years, 5 years and 10 years, Outcomes regarding cardiovascular effects of hormone treatment.

Detailed description

Cohort study in 100 transgender women treated with gender affirming hormone treatment. Follow up affter 1year, 3 years, 5 years and 10 years, Outcomes: Non-calcified and calcified plaque formation by contras coronary CT angiograms Heartfunction by ekko Cardiovaskular risk markers, f. eks. bp Markers of cardiovascular risk in blood and urine

Interventions

OTHERstandard treatment

starndard treatment for transgender women

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* assigned male at birth and eligeble for gender affirming feminizing treatment

Exclusion criteria

none \-

Design outcomes

Primary

Measure	Time frame	Description
coronary plaque formation	1 year	mm3

Countries

Denmark

Contacts

Primary ContactDorte Glintborg

dorte.glintborg@rsyd.dk+4565411807

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026